Cronos Extraction

Toronto, ON, CanadaFounded 2012

Extraction NASDAQ: CRON thecronosgroup.com

Share:X / Twitter LinkedIn Suggest a correction

About Cronos Extraction

Cronos Group's extraction division focuses on innovative cannabinoid research and processing, backed by Altria's strategic investment, with emphasis on biosynthetic cannabinoid production.

Key Facts

1Altria Group invested CAD $2.4 billion for a 45% stake, funding extraction technology R&D
2Partnered with Ginkgo Bioworks to develop fermentation-based production of rare cannabinoids

Latest News

Cronos Group Losses Mount as Cannabis Giant Pivots Strategy

2d ago

CRON reports widening Q1 losses while implementing strategic shift, raising questions about execution in challenging cannabis market environment.

Cronos Q1 Earnings Beat Expectations on International Cannabis Surge

4d ago

CRON delivers strong first quarter results as international cannabis sales drive revenue growth and operational improvements.

Cronos Group Q1 2026 Earnings: Revenue Trends Under Microscope

8d ago

CRON reports first quarter 2026 results as cannabis sector faces margin pressure and regulatory headwinds across key markets.

Cronos Group Surges 7.7% as Cannabis Stock Shows Momentum

8d ago

CRON climbed to $2.80 on elevated volume of 1.38M shares, approaching its 52-week high amid renewed investor interest.

CRON Expands Pre-Roll Line as Cannabis Market Shifts to Value Products

11d ago

Cronos Group broadens pre-roll offerings targeting price-conscious consumers in competitive Canadian market

View all CRON news

Frequently Asked Questions

What is biosynthetic cannabinoid production?

Instead of extracting cannabinoids from plants, biosynthesis uses engineered yeast or bacteria to produce cannabinoids through fermentation, potentially at lower cost and higher purity.

Why did Altria invest in Cronos?

Altria, the tobacco giant behind Marlboro, invested in Cronos to gain exposure to the cannabis industry as a potential growth category amid declining cigarette sales.